SCHEMBL20165475

SCHEMBL20165475

Fc1cc(OC2CNC2)cc(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 9/20 0.50
SLC6A3 Q01959 4/20 0.50
SLC6A4 P31645 4/20 0.50
HTR1A P08908 6/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20168899 0.98 SLC6A2 (0.49) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL23898402 0.87 SLC6A2 (0.57) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL26427836 0.84 SLC6A2 (0.44) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL27105213 0.84 SLC6A2 (0.44) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL20165871 0.81 SLC6A2 (0.48) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL30357881 0.80 SLC6A2 (0.58) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL14956613 0.80 SLC6A2 (0.58) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL19439345 0.80 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4HTR1A
SCHEMBL20165473 0.79 SLC6A2 (0.50) SLC6A2SLC6A3SLC6A4HTR1A
Hydrochloric Acid SCHEMBL22265677 0.79 SLC6A2 (0.47) SLC6A2SLC6A3SLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541784-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Integrative Research Laboratories Sweden AB (SE) 2019-09-25 EP claimed
WO-2018091687-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2018-05-24 WO claimed
US-11780827-B2 Substituted 3-phenoxyazetidin-1-yl-pyrazines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-10 US disclosed
US-11780827-B2 Substituted 3-phenoxyazetidin-1-yl-pyrazines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-10 US disclosed
EP-3541784-B1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) 2023-09-13 EP disclosed
EP-3541784-B1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) 2023-09-13 EP disclosed
US-20230131465-A1 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-04-27 US disclosed
US-20230131465-A1 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-04-27 US disclosed
CN-109963834-B Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission 综合研究实验室瑞典股份公司 2023-04-14 CN disclosed
WO-2021198149-A1 SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES HAVING GPR52 AGONISTIC ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-10-07 WO disclosed
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2020-12-29 US disclosed
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2020-12-29 US disclosed
EP-3541784-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Integrative Research Laboratories Sweden AB (SE) 2019-09-25 EP disclosed
WO-2018091687-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2018-05-24 WO disclosed
WO-2018091687-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission SLC18A1, CHRM1, CHRM2 SLC6A2 21/4885SLC6A3 15/4885SLC6A4 64/4885
US-11780827-B2 Substituted 3-phenoxyazetidin-1-yl-pyrazines GPR52, GPR88, GPR65 SLC6A2 667/4885SLC6A3 2058/4885SLC6A4 1326/4885
US-20230131465-A1 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT GPR52, GPR88, GPR68 SLC6A2 792/4885SLC6A3 1919/4885SLC6A4 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.